Clinical Advances in Hematology & OncologyOptimizing Treatment Sequencing in Renal Cell Carcinoma in an Evolving Therapeutic Landscape

🎓 Expert Commentary / Peer Perspective

Expanding adjuvant and metastatic options complicate treatment sequencing in clear cell RCC. This expert supplement reviews pembrolizumab-based adjuvant therapy, first-line immunotherapy combinations, and subsequent VEGF- and HIF-2α–directed approaches. It emphasizes prior exposure, disease tempo, recurrence timing, and tolerability. Randomized trials inform individual treatment choices, but no single optimal sequence is established. Recommendations after adjuvant relapse rely partly on extrapolation and expert judgment.

Clinical Considerations

• Adjuvant evidence differs: KEYNOTE-564 demonstrated an overall survival benefit; the review reports improved disease-free survival but immature survival data for LITESPARK-022.
• First-line selection: Disease burden, IMDC risk, response urgency, comorbidities, and treatment goals inform IO/TKI versus dual-IO selection; direct comparisons are lacking.
• IO retreatment: CONTACT-03 and TiNivo-2 did not support adding checkpoint blockade after prior IO progression; late post-adjuvant relapse remains less certain.
• Post-IO options: The review reports longer progression-free survival with belzutifan–lenvatinib versus cabozantinib in LITESPARK-011, without a statistically significant survival benefit.
• Toxicity tradeoffs: VEGF-directed regimens require attention to hypertension, diarrhea, and hand-foot syndrome; belzutifan introduces anemia and hypoxia concerns.

Practice Applications

• Review prior agents, recurrence interval, disease tempo, and residual toxicity before interpreting the panel’s proposed sequencing approaches.
• Distinguish randomized post-IO evidence from expert extrapolation to adjuvant relapse; avoid treating six months as a validated rechallenge threshold.
• Integrate multidisciplinary toxicity education and monitoring, with dose modifications guided by current prescribing information and individual tolerability.
• Verify current labels and guideline categories before publication; the source contains inconsistent statements about preferred first-line regimens.